Menu
← Oncology Approval Tracker
FDA DECISION ·
Braftovi + cetuximab + mFOLFOX6
encorafenib with cetuximab and mFOLFOX6 · Array BioPharma (Pfizer)
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Patients with metastatic colorectal cancer and an FDA test-confirmed BRAF V600E mutation, treated with encorafenib, cetuximab and mFOLFOX6.
LAMPGEN ANALYSIS
Why it matters
The December action brought a BRAF-directed combination into frontline use; distinguish it from the chemotherapy-free doublet used after prior therapy. The FDA granted traditional approval in February 2026.
What research teams should watch
Get BRAF results before selecting a first regimen and track component-specific dose holds and treatment exposure.
Related study operations checklist
See the staffing responsibilities, timing, and handoff questions for this study setting.
Molecularly selected metastatic diseasePRIMARY RECORDS